摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)acetic acid | 543732-34-9

中文名称
——
中文别名
——
英文名称
2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)acetic acid
英文别名
2,2-dimethyl-5-(carboxymethylene)-1,3-dioxolan-4-one;(2,2-Dimethyl-5-oxo-[1,3]dioxolan-4-ylidene)-acetic acid
2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)acetic acid化学式
CAS
543732-34-9
化学式
C7H8O5
mdl
——
分子量
172.138
InChiKey
YVPQVDVWOGWULH-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    346.1±42.0 °C(Predicted)
  • 密度:
    1.464±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.6
  • 重原子数:
    12
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.43
  • 拓扑面积:
    72.8
  • 氢给体数:
    1
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)acetic acid 、 2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)acetic acid 在 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下, 以 二氯甲烷 为溶剂, 反应 48.0h, 生成 C23H22Cl2NO6Pol
    参考文献:
    名称:
    Solid Phase Synthesis of Novel Pyrrolidinedione Analogs as Potent HIV-1 Integrase Inhibitors
    摘要:
    A novel series of HIV-1 integrase inhibitors were identified from a 100 member (4R(1) x 5R(2) x 5R(3)) library of pyrrolidinedione amides. A solid-phase route was developed which facilitates the simultaneous variation at R-1, R-2, and R-3 of the pyrrolidinedione scaffold. The resulting library samples were assayed for HIV-1 integrase activity and analyzed to determine the R-1, R-2, and R-3 reagent contributions towards the activity.
    DOI:
    10.1021/cc9001026
  • 作为产物:
    描述:
    2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)acetic acid 、 在 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下, 以 二氯甲烷 为溶剂, 反应 48.0h, 生成 2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)acetic acid
    参考文献:
    名称:
    Solid Phase Synthesis of Novel Pyrrolidinedione Analogs as Potent HIV-1 Integrase Inhibitors
    摘要:
    A novel series of HIV-1 integrase inhibitors were identified from a 100 member (4R(1) x 5R(2) x 5R(3)) library of pyrrolidinedione amides. A solid-phase route was developed which facilitates the simultaneous variation at R-1, R-2, and R-3 of the pyrrolidinedione scaffold. The resulting library samples were assayed for HIV-1 integrase activity and analyzed to determine the R-1, R-2, and R-3 reagent contributions towards the activity.
    DOI:
    10.1021/cc9001026
点击查看最新优质反应信息

文献信息

  • [EN] PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS<br/>[FR] COMPOSÉS DE PYRROLINONE-CARBOXAMIDE UTILES EN TANT QU'INHIBITEURS DE LIPASE ENDOTHÉLIALE
    申请人:BRISTOL MYERS SQUIBB CO
    公开号:WO2013048982A1
    公开(公告)日:2013-04-04
    The present invention provides compounds of Formula (I) or Formula (III): [INSERT CHEMICAL STRUCTURE HERE] (I) [INSERT CHEMICAL STRUCTURE HERE] (III) as defined in the specification and compositions comprising any of such novel compounds. These compounds are endothelial lipase inhibitors which may be used as medicaments.
    本发明提供了Formula (I)或Formula (III)的化合物:[在此插入化学结构] (I) [在此插入化学结构] (III),如规范中定义的,并包括任何这类新化合物的组合物。这些化合物是内皮脂酶抑制剂,可用作药物。
  • HIV Integrase inhibitors
    申请人:——
    公开号:US20030176495A1
    公开(公告)日:2003-09-18
    The present invention relates to the inhibition of HIV integrase, and to the treatment of AIDS or ARC by administering compounds of the following formula, or a tautomer of said compound, or a pharmaceutically acceptable salt, solvate or prodrug thereof: 1 wherein R 1 , R 2 and B 1 are as defined herein.
    本发明涉及抑制HIV整合酶,以及通过给予以下化合物、该化合物的互变异构体、或其药学上可接受的盐、溶剂化合物或前药来治疗艾滋病或ARC的方法:1其中R1、R2和B1如本文所定义。
  • [EN] PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS<br/>[FR] COMPOSÉS PYRROLINONE CARBOXAMIDE UTILES COMME INHIBITEURS DE LIPASE ENDOTHÉLIALE
    申请人:BRISTOL MYERS SQUIBB CO
    公开号:WO2013048928A1
    公开(公告)日:2013-04-04
    The present invention provides compounds of Formula (I): (I), as defined in the specification and compositions comprising any of such novel compounds. These compounds are endothelial lipase inhibitors which may be used as medicaments.
    本发明提供了以下式(I)的化合物:(I),如规范中定义的,并包括任何此类新化合物的组合物。这些化合物是内皮酶抑制剂,可用作药物。
  • Process for the preparation of Z-5-carboxymethylene-1,3-dioxolan-4-ones
    申请人:Nugent A. William
    公开号:US20060047129A1
    公开(公告)日:2006-03-02
    A process for preparing Z-5-carboxymethylene-1,3-dioxolan-4-ones is provided which includes the steps of reacting a bis-ketal or bis-acetal of tartaric acid with a potassium containing base to form the carboxymethylene-1,3-dioxolan-4-one. A process for preparing HIV integrase inhibitors employing the carboxymethylene-1,3-dioxolan-4-one inhibitor is also provided.
    提供一种制备Z-5-羧甲烯基-1,3-二氧杂环戊酮的方法,包括以下步骤:将酒石酸缩醛或双缩醛与含碱基反应,形成羧甲烯基-1,3-二氧杂环戊酮。还提供一种利用羧甲烯基-1,3-二氧杂环戊酮抑制剂制备HIV整合酶抑制剂的方法。
  • HIV integrase inhibitors
    申请人:——
    公开号:US20030181490A1
    公开(公告)日:2003-09-25
    The present invention relates to the inhibition of HIV integrase, and to the treatment of AIDS or ARC by administering compounds of the formula 1 wherein R 1 is C 1 -C 4 alkyl, carbocyclic radical, heterocyclic radical, aryl-C 1 -C 2 alkylene, aryloxy-C 1 -C 2 alkylene, alkoxy-CC(O)—, wherein R 1 is optionally substituted from 1-3 times with halo, C 1 -C 2 alkyl or C 1 -C 2 alkoxy, or R 1 is H; R 2 is H or C 1 -C 4 alkyl; R 3 is H, C 1 -C 4 alkyl or phenyl-C 0 -C 2 alkylene which is optionally substituted with 1-3 R 5 ; R 4a is carbocylic radical, heterocyclic radical, aryloxy, aryl-C 1 -C 4 alkylene, aryl-cyclopropylene, aryl-NHC(O)—, wherein R 4a is optionally substituted with 1-3 R 5 ; and wherein each R 5 is independently selected from H, halo, C 1 -C 4 alkyl, C 1 -C 4 alkenyl, C 1 -C 4 haloalkyl, C 1 -C 4 alkoxy, R 6 -phenyl, R 6 -phenoxy, R 6 -benzyl, R 6 -benzyloxy, NH 2 C (O)—, alkyl-NHC(O)—, wherein R 6 is H, halo; Z is a bond or a substituted or unsubstituted C 1 -C 4 alkylene group; and B 2 is 2
    本发明涉及抑制HIV整合酶的化合物,并通过给予式1中的化合物治疗艾滋病或ARC,其中R1为C1-C4烷基,碳环基,杂环基,芳基-C1-C2烷基,芳氧基-C1-C2烷基,烷氧基-CC(O)-,其中R1可以用卤素,C1-C2烷基或C1-C2烷氧基从1-3次取代,或R1为H;R2为H或C1-C4烷基;R3为H,C1-C4烷基或苯基-C0-C2烷基,该苯基-C0-C2烷基可以选择性地用1-3个R5取代;R4a为碳环基,杂环基,芳氧基,芳基-C1-C4烷基,芳基环丙基,芳基-NHC(O)-,其中R4a可以选择性地用1-3个R5取代;每个R5都是独立选择的H,卤素,C1-C4烷基,C1-C4烯基,C1-C4卤代烷基,C1-C4烷氧基,R6-苯基,R6-苯氧基,R6-苄基,R6-苄氧基,NH2C(O)-,烷基-NHC(O)-,其中R6为H,卤素;Z为键或取代或未取代的C1-C4烷基;B2为2。
查看更多